Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STAR-LLD-TDS
- Development stage
- Unknown
- Lead developer
- Starton Therapeutics
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Transdermal, Oral
01
Overview
STAR-LLD-TDS is a proprietary transdermal patch formulation of lenalidomide developed by Starton Therapeutics. It delivers low-dose lenalidomide continuously through the skin using a transdermal delivery system (TDS), aiming to maintain steady therapeutic blood levels and reduce peak-related toxicities associated with oral dosing. This continuous delivery approach is designed to improve tolerability and efficacy in patients with multiple myeloma and chronic lymphocytic leukemia (CLL), potentially allowing for longer-term maintenance therapy with fewer side effects. Preclinical studies have shown superior tumor reduction and progression-free survival compared to standard oral lenalidomide regimens, while early clinical trials indicate promising efficacy and safety profiles[2][3][4][7][9]. The mechanism of action is based on the immunomodulatory effects of lenalidomide.
- Other names
- STAR-LLD-TDSSTAR-LLD transdermal delivery systemSTAR-LLD TDS
02
Targets
CRBN (Cereblon)IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on STAR-LLD-TDS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STAR-LLD-TDS.